Boston Scientific has exercised its option to wholly acquire Millipede, having purchased a $90m stake in the mitral regurgitation treatment device maker last year.
Medical device manufacturer Boston Scientific has acquired the rest of the shares in one of its portfolio companies, US-based mitral regurgitation system developer Millipede Medical, for $325m.
The transaction is expected to close within the first quarter of this year. Millipede will receive an additional $125m payment if it reaches an unspecified commercial milestone.
Founded in 2012, Millipede is developing a medical device to treat patients suffering from severe mitral regurgitation – a condition that causes blood to flow the…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
